Back to products

LuciPona 45 mg Tablet

Brand Name: LuciPona

Molecule: Ponatinib

Strength: 45 mg

Quantity: 30 Tablets

Form: Tablet

Packaging Type: Bottle

Manufacturer/Marketed By: Lucius Pharma

Country of Origin: Laos

References

LuciPona (Ponatinib), a potent kinase inhibitor specifically formulated to target chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Each tablet of LuciPona contains 45mg of Ponatinib, designed for adult patients who have shown resistance or intolerance to at least two prior kinase inhibitors.

LuciPona is indicated for:

Chronic phase (CP) CML provides a vital treatment option for patients facing challenges with previous therapies.
– Accelerated phase (AP) or blast phase (BP) CML, as well as Ph+ALL, ensuring patients without other kinase inhibitors available receive the care they need.
– T315I-positive CML or Ph+ALL across all phases, offering a targeted approach for those with this specific mutation.